Systematic Comparison of Peptidic Proteasome Inhibitors Highlights the α-Ketoamide Electrophile as an Auspicious Reversible Lead Motif

Synthesis and Pharmacology of Proteasome Inhibitors

(2013) Andreas Rentsch et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development

(2012) Eva Maria Huber et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Covalent and non-covalent reversible proteasome inhibition

(2012) Philipp Beck et al.   BIOLOGICAL CHEMISTRY

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

(2012) Eva M. Huber et al.   CELL

Oxidative Homologation of Aldehydes to α-Ketoaldehydes by using Iodoform, o-Iodoxybenzoic Acid, and Dimethyl Sulf­oxide

(2012) Andrea Zall et al.   EUROPEAN JOURNAL OF ORGANIC CHEMISTRY

New Proteasome Inhibitors in Myeloma

(2012) Panisinee Lawasut et al.   Current Hematologic Malignancy Reports

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

(2011) J. Yang et al.   DRUG METABOLISM AND DISPOSITION

Elucidation of the α-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition

(2010) Melissa Ann Gräwert et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach

(2010) Michał Mroczkiewicz et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

(2009) M. J. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE